%0 Journal Article
%A Alfonso, Fernando
%A Pérez-Vizcayno, María José
%A Cuesta, Javier
%A García Del Blanco, Bruno
%A García-Touchard, Arturo
%A López-Mínguez, José Ramón
%A Masotti, Mónica
%A Zueco, Javier
%A Cequier, Angel
%A Velázquez, Maite
%A Moreno, Raúl
%A Mainar, Vicente
%A Domínguez, Antonio
%A Moris, Cesar
%A Molina, Eduardo
%A Rivero, Fernando
%A Jiménez-Quevedo, Pilar
%A Gonzalo, Nieves
%A Fernández-Pérez, Cristina
%A RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology)
%T 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
%D 2018
%U http://hdl.handle.net/10668/12505
%X This study sought to compare the long-term safety and efficacy of drug-eluting balloons (DEB) and everolimus-eluting stents (EES) in patients with in-stent restenosis (ISR) of drug-eluting stents (DES). Treatment of patients with DES-ISR remains a challenge. The RIBS IV (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents) trial is a prospective multicenter randomized clinical trial comparing DEB and EES in patients with DES-ISR. The pre-specified comparison of the 3-year clinical outcomes obtained with these interventions is the main objective of the present study. A total of 309 patients with DES-ISR were randomized to DEB (n = 154) or EES (n = 155). At angiographic follow-up, the in-segment minimal lumen diameter was larger in the EES arm (2.03 ± 0.7 mm vs. 1.80 ± 0.6 mm; p 1 year) target lesion revascularization (2.6% vs. 4%) and target vessel revascularization (4% vs. 6.6%) was similar in the 2 arms. Rates of cardiac death (3.9% vs. 3.2%), myocardial infarction (2.6% vs. 4.5%), and stent thrombosis (1.3% vs. 2.6%) at 3 years were also similar in both arms. The 3-year clinical follow-up of this randomized clinical trial demonstrates that in patients with DES-ISR, EES reduce the need for repeat interventions compared with DEB. (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloons vs Everolimus-Eluting Stents [RIBS IV]; NCT01239940).
%K drug-eluting ballon(s)
%K drug-eluting stent(s)
%K everolimus-eluting stent(s)
%K in-stent restenosis
%~